Document is current
Any future updates will be listed below
-
Authors
Grech, Olivia
Mugo, Caroline
Hill, Lisa J.
Heaselgrave, Samuel R.
Alimajstorovic, Zerin
Yiangou, Andreas
Lyons, Hannah S.
Mitchell, James
Lavery, Gareth G.
Fulton, Daniel
Sinclair, Alexandra J.
-
Funding
Funding for this research was provided by:
Sir Jules Thorn Charitable Trust (Award for Biomedical Research)
Sir Jules Thorn Charitable Trust (Award for Biomedical Research)
Sir Jules Thorn Charitable Trust (Award for Biomedical Research)
Association of British Neurologists and Guarantors of the Brain (Fellowship)
U.S. Department of Defense
- License Information
-
More Information
Article History
Received: 27 August 2025
Accepted: 20 January 2026
First Online: 11 February 2026
Declarations
:
: OG reports scientific consultancy fees from Invex Therapeutics, outside the scope of this work. AJS reports has consulted for Novartis, AbbVie, Vertex and Orion Pharma and speaker fees from Teva Uk and Novartis. She was previously a Director and Chief Scientific Officer (CSO) with shares at Invex Therapeutics.
